Recent News

• 01.12.2026 - Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes
• 12.18.2025 - Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia
• 12.05.2025 - Announcement relating to despatch of Rule 15 proposal
• 12.03.2025 - Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting
• 12.01.2025 - Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting
• 11.17.2025 - Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”

Recent Filings

• 01.12.2026 - EX-99.1 EX-99.1
• 01.12.2026 - 8-K Current report
• 12.19.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 12.18.2025 - EX-99.1 EX-99.1
• 12.18.2025 - 8-K Current report
• 12.09.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 12.09.2025 - 8-K Current report
• 12.03.2025 - DEFM14A Definitive proxy statement relating to merger or acquisition
• 12.02.2025 - PRER14A Preliminary Proxy Soliciting materials
• 11.19.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material